Hippocratic AI is expanding its presence in life sciences by acquiring Grove AI, a startup focused on agentic AI for pharma R&D and clinical trial operations. The acquisition strengthens Hippocratic AI’s capabilities in biopharma and medtech by adding technology designed to streamline clinical trial participant engagement, recruitment, and follow-up across voice, text, and email. Grove AI’s platform, including its AI agent “Grace,” has supported more than 10 million patient interactions and powered over 50 phase 2 and 3 clinical trials, positioning Hippocratic AI to accelerate enterprise-scale deployment of agentic AI in highly regulated life sciences environments.
“There are really specific compliance needs that need to be met here—they’re not like ‘nice to haves’, they’re ‘have to haves’. That’s part of what we’re all building together. Even in clinical trials, there’s certain regulations, certain things that an agent can do, certain things that really a human has to be the last one to verify enrollment, certain steps of enrollment and disclosure,” Shah noted. “That’s requiring a whole new approach. It’s requiring the resources and the ability to really innovate at the model level that Hippocratic has had. You can’t just prompt your way through it, by and large, and so we’ve really brought together this whole team to really accelerate that journey.”